title: New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
abstract: Both seasonal and pandemic influenza cause considerable morbidity and mortality globally. In addition, the ongoing threat of new, unpredictable influenza pandemics from emerging variant strains cannot be underestimated. Recently bioCSL (previously known as CSL Biotherapies) sponsored a symposium 'New Wisdom to Defy an Old Enemy' at the 4th Influenza Vaccines for the World Congress in Valencia, Spain. This symposium brought together a renowned faculty of experts to discuss lessons from past experience, novel influenza vaccine developments, and new methods to increase vaccine acceptance and coverage. Specific topics reviewed and discussed included new vaccine development efforts focused on improving efficacy via alternative administration routes, dose modifications, improved adjuvants, and the use of master donor viruses. Improved safety was also discussed, particularly the new finding of an excess of febrile reactions isolated to children who received the 2010 Southern Hemisphere (SH) trivalent inactivated influenza vaccine (TIV). Significant work has been done to both identify the cause and minimize the risk of febrile reactions in children. Other novel prophylactic and therapeutic advances were discussed including immunotherapy. Standard IVIg and hIVIg have been used in ferret studies and human case reports with promising results. New adjuvants, such as ISCOMATRIX™ adjuvant, were noted to provide single-dose, prolonged protection with seasonal vaccine after lethal H5N1 virus challenge in a ferret model of human influenza disease. The data suggest that adjuvanted seasonal influenza vaccines may provide broader protection than unadjuvanted vaccines. The use of an antigen-formulated vaccine to induce broad protection between pandemics that could bridge the gap between pandemic declaration and the production of a homologous vaccine was also discussed. Finally, despite the availability of effective vaccines, most current efforts to increase influenza vaccine coverage rates to higher levels (i.e., above 70-80%) have been ineffective in highly developed countries where the vaccine is used, hindered by the public's skepticism towards vaccines in general. New educational and social media methods to increase vaccine acceptance and coverage were discussed. While the first priority should be the development of improved influenza vaccines, a particular focus on the aging global population is critical. It is also important to draw lessons from other academic disciplines that can help to inform vaccine education programs, policy, and communication. By tailoring communications and patient education using an understanding of cognitive bias and the model of preferred cognitive styles, the likelihood of effecting desirable health decisions can be maximized, leading to improved vaccine coverage and control of influenza and other vaccine-preventable diseases.
authors.affiliation: Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. poland.gregory@mayo.edu
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Poland
authors.forename: Douglas M
authors.initials: DM
authors.lastname: Fleming
authors.forename: John J
authors.initials: JJ
authors.lastname: Treanor
authors.forename: Eugene
authors.initials: E
authors.lastname: Maraskovsky
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Luke
authors.forename: Emma M A
authors.initials: EM
authors.lastname: Ball
authors.forename: Caroline M
authors.initials: CM
authors.lastname: Poland
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000008:administration & dosage; D003226:Congresses as Topic; D004195:Disease Models, Animal; D004338:Drug Combinations; D005289:Ferrets; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D053118:Influenza A Virus, H1N1 Subtype; D053122:Influenza A Virus, H3N2 Subtype; D053124:Influenza A Virus, H5N1 Subtype; D064149:Influenza Pandemic, 1918-1919; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D007251:Influenza, Human / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D009976:Orthomyxoviridae Infections / Q000517:prevention & control; D058873:Pandemics; D010342:Patient Acceptance of Health Care; D010743:Phospholipids / Q000008:administration & dosage; D012503:Saponins / Q000008:administration & dosage; D013030:Spain; D014611:Vaccination / Q000523:psychology; D015164:Vaccines, Inactivated / Q000009:adverse effects
chemical_list: D000276:Adjuvants, Immunologic; D004338:Drug Combinations; C493786:ISCOMATRIX; D016756:Immunoglobulins, Intravenous; D007252:Influenza Vaccines; D010743:Phospholipids; D012503:Saponins; D015164:Vaccines, Inactivated; D002784:Cholesterol